Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Global Life Sciences Ventures

Global Life Sciences Ventures

Global Life Sciences Ventures is a venture capital fund focused on life sciences.

All edits

Edits on 20 Nov, 2022
Volha Lapatsik
Volha Lapatsik edited on 20 Nov, 2022
Infobox
Volha Lapatsik
Volha Lapatsik edited on 20 Nov, 2022
Infobox
Invested in
Volha Lapatsik
Volha Lapatsik edited on 20 Nov, 2022
Infobox
Invested in
Volha Lapatsik
Volha Lapatsik edited on 20 Nov, 2022
Infobox
Invested in
Volha Lapatsik
Volha Lapatsik edited on 20 Nov, 2022
Infobox
Invested in
Volha Lapatsik
Volha Lapatsik edited on 20 Nov, 2022
Infobox
Edits on 28 Jul, 2022
Golden AI"remove blacklisted domain URLs"
Golden AI edited on 28 Jul, 2022
Edits made to:
Article
Article

Global Life Science Ventures also invested in selected later stage companies, including buy-outs. For this purpose, GLSV provided finance, advice and access to expertise and networks. The group advised and managed funds totaling more than € 200 million. With offices in Germany and Switzerland, GLSV acted as one team with a global perspective. The first fund started its activities in 1996 and invested in 18 companies. The second fund GLSV II started in 2001 and invested in 18 companies primarily in Europe and the US. After termination of the investment period, the fund exited the remaining assets in 2015 and is in liquidation.

...

Global Life Sciences Ventures' investments include Binx Health, Santaris Pharma, Action Pharma, Coapt Systems, Agendia, Nitec Pharma, Pieris Pharmaceuticals, NeurogesX and Spinal Cord Therapeutics.

...

Their exited investments include Santaris Pharma, NeurogesX, Cytos, Zalicus, Coapt Systems, Coley Pharmaceutical Group, Roche Glycart, Intercell and Pieris Pharmaceuticals.

Edits on 17 May, 2022
Katrina-Kay Pettitt"prospector:1525:750074"
Katrina-Kay Pettitt edited on 17 May, 2022
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 5 Apr, 2022
Katrina-Kay Pettitt"prospector:1398:577065"
Katrina-Kay Pettitt edited on 5 Apr, 2022
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 13 Apr, 2021
Neelam Jhaveri
Neelam Jhaveri approved a suggestion from Golden's AI on 13 Apr, 2021
Edits made to:
Article (+9/-9 characters)
Article

Their exited investments include Santaris Pharma, NeurogesX, Cytos, Zalicus, Coapt Systems, Coley Pharmaceutical Group, Roche Glycart, IntercellIntercell and Pieris Pharmaceuticals.

Edits on 28 Mar, 2021
Golden AI
Golden AI edited on 28 Mar, 2021
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 10 Dec, 2019
Aleksander Holm
Aleksander Holm approved a suggestion from Golden's AI on 10 Dec, 2019
Edits made to:
Article (+22/-22 characters)
Article

Global Life Sciences Ventures' investments include Binx Health, Santaris Pharma, Action Pharma, Coapt Systems, Agendia, Nitec Pharma, Pieris PharmaceuticalsPieris Pharmaceuticals, NeurogesX and Spinal Cord Therapeutics.

Aleksander Holm
Aleksander Holm approved a suggestion from Golden's AI on 10 Dec, 2019
Edits made to:
Article (+7/-7 characters)
Article

Global Life Sciences Ventures' investments include Binx Health, Santaris Pharma, Action Pharma, Coapt Systems, AgendiaAgendia, Nitec Pharma, Pieris Pharmaceuticals, NeurogesX and Spinal Cord Therapeutics.

Edits on 9 Dec, 2019
Aleksander Holm
Aleksander Holm approved a suggestion from Golden's AI on 9 Dec, 2019
Edits made to:
Article (+20/-20 characters)
Article

Global Life Science Ventures is a venture capital firmventure capital firm focusing on the life science sector. The firm is dedicated to supporting early-stage groups, originating from universities, scientific institutions or industry. The firm was founded in 1996 and is based in Munich, Germany.

Aleksander Holm
Aleksander Holm approved a suggestion from Golden's AI on 9 Dec, 2019
Edits made to:
Article (+26/-26 characters)
Article

Their exited investments include Santaris Pharma, NeurogesX, Cytos, Zalicus, Coapt Systems, Coley Pharmaceutical GroupColey Pharmaceutical Group, Roche Glycart, Intercell and Pieris Pharmaceuticals.

Aleksander Holm
Aleksander Holm approved a suggestion from Golden's AI on 9 Dec, 2019
Edits made to:
Article (+6/-6 characters)
Article

Global Life Science Ventures is a venture capital firm focusing on the life science sector. The firm is dedicated to supporting early-stage groups, originating from universities, scientific institutions or industry. The firm was founded in 1996 and is based in MunichMunich, Germany.

Aleksander Holm
Aleksander Holm approved a suggestion from Golden's AI on 9 Dec, 2019
Edits made to:
Article (+7/-7 characters)
Article

Global Life Science Ventures also invested in selected later stage companies, including buy-outs. For this purpose, GLSV provided finance, advice and access to expertise and networks. The group advised and managed funds totaling more than € 200 million. With offices in GermanyGermany and Switzerland, GLSV acted as one team with a global perspective. The first fund started its activities in 1996 and invested in 18 companies. The second fund GLSV II started in 2001 and invested in 18 companies primarily in Europe and the US. After termination of the investment period, the fund exited the remaining assets in 2015 and is in liquidation.

Aleksander Holm
Aleksander Holm approved a suggestion from Golden's AI on 9 Dec, 2019
Edits made to:
Article (+13/-13 characters)
Article

Global Life Sciences Ventures' investments include Binx Health, Santaris Pharma, Action Pharma, Coapt SystemsCoapt Systems, Agendia, Nitec Pharma, Pieris Pharmaceuticals, NeurogesX and Spinal Cord Therapeutics.

Aleksander Holm
Aleksander Holm approved a suggestion from Golden's AI on 9 Dec, 2019
Edits made to:
Article (+15/-15 characters)
Article

Global Life Sciences Ventures' investments include Binx Health, Santaris PharmaSantaris Pharma, Action Pharma, Coapt Systems, Agendia, Nitec Pharma, Pieris Pharmaceuticals, NeurogesX and Spinal Cord Therapeutics.

Aleksander Holm
Aleksander Holm approved a suggestion from Golden's AI on 9 Dec, 2019
Edits made to:
Article (+11/-11 characters)
Article

Global Life Science Ventures also invested in selected later stage companies, including buy-outs. For this purpose, GLSV provided finance, advice and access to expertise and networks. The group advised and managed funds totaling more than € 200 million. With offices in Germany and SwitzerlandSwitzerland, GLSV acted as one team with a global perspective. The first fund started its activities in 1996 and invested in 18 companies. The second fund GLSV II started in 2001 and invested in 18 companies primarily in Europe and the US. After termination of the investment period, the fund exited the remaining assets in 2015 and is in liquidation.

Golden logo
By using this site, you agree to our Terms & Conditions.